Don't forget Aug. 2024: " This open label, rand
Post# of 148101
(Total Views: 371)
Posted On: 11/04/2024 6:58:36 PM
Don't forget Aug. 2024:
" This open label, randomized (1:1), multicenter trial will evaluate the anti-tumor activity (via overall response rate, ORR) of leronlimab at doses of 350 mg and 700 mg in combination TAS-102 and bevacizumab in approximately 60 patients with CCR5+, microsatellite stable metastatic CRC (mCRC)."
___
Ai excerpt:
Bevacizumab, also known as Avastin, is a targeted cancer drug treatment that's used in combination with chemotherapy or as a single agent to treat a variety of cancers:
Solid tumors
Bevacizumab is approved in 134 countries to treat many types of solid tumors, including breast, colorectal, lung, ovarian, renal cell, and cervical cancer.
Glioblastoma
Bevacizumab is approved to treat progressive glioblastoma after previous therapy.
Metastatic renal cell carcinoma
Bevacizumab is approved to treat metastatic renal cell carcinoma in combination with interferon alfa.
Bevacizumab is an anti-angiogenic therapy that prevents the growth of new blood vessels. It's administered intravenously as a clear, colorless solution in doses of 5, 7.5, 10, or 15 mg/kg.
___
134 countries & a laundry list of cancers.
This is going to be extremely significant for LL.
On our August news, MGK & others pointed the potential turn-around time to data read-out on ORR can be a very fairly quick timeline.
If I remember right, others also mentioned great ORR results can basis Cytodyn filing for early, Conditional Approval.
I think that potential is particularly why the FDA relationship is reinforced.
An optic message to shareholders of --- think to the near & distant future(s).
Because now Leronlimab's got this.
" This open label, randomized (1:1), multicenter trial will evaluate the anti-tumor activity (via overall response rate, ORR) of leronlimab at doses of 350 mg and 700 mg in combination TAS-102 and bevacizumab in approximately 60 patients with CCR5+, microsatellite stable metastatic CRC (mCRC)."
___
Ai excerpt:
Bevacizumab, also known as Avastin, is a targeted cancer drug treatment that's used in combination with chemotherapy or as a single agent to treat a variety of cancers:
Solid tumors
Bevacizumab is approved in 134 countries to treat many types of solid tumors, including breast, colorectal, lung, ovarian, renal cell, and cervical cancer.
Glioblastoma
Bevacizumab is approved to treat progressive glioblastoma after previous therapy.
Metastatic renal cell carcinoma
Bevacizumab is approved to treat metastatic renal cell carcinoma in combination with interferon alfa.
Bevacizumab is an anti-angiogenic therapy that prevents the growth of new blood vessels. It's administered intravenously as a clear, colorless solution in doses of 5, 7.5, 10, or 15 mg/kg.
___
134 countries & a laundry list of cancers.
This is going to be extremely significant for LL.
On our August news, MGK & others pointed the potential turn-around time to data read-out on ORR can be a very fairly quick timeline.
If I remember right, others also mentioned great ORR results can basis Cytodyn filing for early, Conditional Approval.
I think that potential is particularly why the FDA relationship is reinforced.
An optic message to shareholders of --- think to the near & distant future(s).
Because now Leronlimab's got this.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼